NX Development Corp.

NX Development Corp. is a specialty pharmaceutical company primarily known for the commercialization of Gleolan (aminolevulinic acid hydrochloride) in the United States. Gleolan is an FDA-approved optical imaging agent used as an adjunct for the visualization of malignant tissue during surgery in patients with high-grade gliomas. The company focuses on fluorescence-guided surgery to improve surgical outcomes by allowing for more precise tumor resection. In 2022, NX Development Corp. was acquired by medac GmbH, a global pharmaceutical company based in Germany. This acquisition integrated NXDC's expertise in neuro-oncology into medac's broader portfolio of therapeutic and diagnostic products.